Dongqing Sun

Title: Dongqing Sun: Patent Activity in BTK Degrader Research.

Introduction

Dongqing Sun is an inventor associated with Beijing, China. His listed patent work concerns compounds designed to degrade Bruton's tyrosine kinase (BTK), a protein targeted in therapeutic research. The supplied information identifies BeOne Medicines GmbH as his company.

Latest Patents

The provided data lists one patent for Sun: “(R) and (S)-3-(tert-butyl)-N-(1-(4-(6-(6-(4-((1-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide as Bruton's tyrosine kinase (BTK) degraders.” The patent description also covers methods of preparation and uses of the compounds. The listed patent count is 1 patent.

Career Highlights

Sun’s listed invention focuses on chemical compounds intended to act as BTK degraders. The supplied information associates his work with BeOne Medicines GmbH and places him in Beijing, China.

Collaborations

The provided data names Bailin Lei and Huaqing Liu as Sun’s coworkers. Their inclusion indicates a professional connection, but no specific roles or contributions to the listed patent were provided.

Conclusion

Dongqing Sun’s listed patent activity centers on BTK-degrader compounds, with the supplied information connecting his work to BeOne Medicines GmbH and collaborators Bailin Lei and Huaqing Liu.